Vinorelbine
- Generic Name
- Vinorelbine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C45H54N4O8
- CAS Number
- 71486-22-1
- Unique Ingredient Identifier
- Q6C979R91Y
- Background
Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC) . It was initially approved in the USA in 1990's for the treatment of NSCLC .
...
- Indication
Vinorelbine tartrate is indicated for adults in the treatment of advanced non-small cell lung cancer (NSCLC), as a single therapy or in combination with other chemotherapeutic drugs .
Used in relapsed or refractory Hodgkin lymphoma, in combination with other chemotherapy agents .
...
- Associated Conditions
- Locally Advanced Non-Small Cell Lung Cancer, Metastatic Breast Cancer, Metastatic Cervical Cancer, Metastatic Non-Small Cell Lung Cancer, Recurrent Cervical Cancer, Soft Tissue Sarcoma
- Associated Therapies
- -
Study of Cipterbin®, Used Alone or With Vinorelbine in Patients With HER2/Neu-overexpressed Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2011-09-23
- Last Posted Date
- 2011-09-23
- Lead Sponsor
- Shanghai CP Guojian Pharmaceutical Co., Ltd.
- Target Recruit Count
- 109
- Registration Number
- NCT01439191
- Locations
- 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China
A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases
- Conditions
- Interventions
- First Posted Date
- 2011-03-01
- Last Posted Date
- 2018-12-17
- Lead Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Target Recruit Count
- 32
- Registration Number
- NCT01305941
- Locations
- 🇺🇸
UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
🇺🇸Carolinas Healthcare System, Charlotte, North Carolina, United States
🇺🇸University Of Alabama at Birmingham, Birmingham, Alabama, United States
Safety and Efficacy of INCB007839 With Trastuzumab and Vinorelbine in Patients With Metastatic HER2+ Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-12-06
- Last Posted Date
- 2012-01-25
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 20
- Registration Number
- NCT01254136
Oral Vinorelbine in Combination With Trastuzumab for Metastatic Breast Cancer
- Conditions
- First Posted Date
- 2010-11-17
- Last Posted Date
- 2015-05-21
- Lead Sponsor
- Vejle Hospital
- Target Recruit Count
- 10
- Registration Number
- NCT01242449
- Locations
- 🇩🇰
Dept. of Oncology, Aalborg Sygehus, Aalborg, Denmark
🇩🇰Department of Oncology, Vejle Hospital, Vejle, Denmark
🇩🇰Dept. of Oncology, Esbjerg Hospital, Esbjerg, Denmark
Residual Hypermethylation in Early Stage Non-Small Cell Lung Cancer (NSCLC) As Part of Adjuvant Therapy and Preventive Strategy
- Conditions
- Interventions
- First Posted Date
- 2010-09-27
- Last Posted Date
- 2015-02-24
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 6
- Registration Number
- NCT01209520
- Locations
- 🇺🇸
University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States
A Study of Tarceva (Erlotinib) in Elderly Patients With Advanced Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-09-08
- Last Posted Date
- 2015-07-27
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 114
- Registration Number
- NCT01196078
Trastuzumab and Vinorelbine in Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-08-20
- Last Posted Date
- 2019-01-23
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 31
- Registration Number
- NCT01185509
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-06-07
- Last Posted Date
- 2013-03-13
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT01137994
LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment
- Conditions
- Interventions
- First Posted Date
- 2010-05-18
- Last Posted Date
- 2019-07-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 508
- Registration Number
- NCT01125566
- Locations
- 🇦🇹
Ordensklinikum Linz GmbH - Barmherzige Schwestern, Linz, Austria
🇦🇷Sanatorio Parque, Rosario, Argentina
🇺🇸Ironwood Cancer and Research Centers, Chandler, Arizona, United States
Safety Study of Cetuximab in Combination With Cisplatin and Vinorelbine to Treat Advanced Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-04-23
- Last Posted Date
- 2015-12-24
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 72
- Registration Number
- NCT01109524
- Locations
- 🇺🇸
Cancer Care Institute, Los Angeles, California, United States
🇺🇸Elite Research Institute, Miami, Florida, United States
🇺🇸Mid Dakota Clinic, Pc, Bismarck, North Dakota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.